What Is Semaglutide? A Research-Backed Guide to the Most Studied GLP-1

What Is Semaglutide? A Research-Backed Guide to the Most Studied GLP-1

Choice Peptide Labs | 14 min read | STEP 1-5+ clinical trials | June 2026

Semaglutide has one of the largest clinical trial programs of any peptide-based compound in modern research history. The STEP program spans 5+ major trials, thousands of participants, and publications in NEJM, JAMA, and The Lancet.

What Is Semaglutide?

A GLP-1 receptor agonist developed by Novo Nordisk. It mimics the natural incretin hormone GLP-1 — stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on brain receptors that regulate appetite. Engineered for once-weekly dosing by resisting DPP-4 degradation.

The STEP Clinical Trial Program

STEP 1 (NEJM, 2021): 1,961 adults, 68 weeks. Semaglutide 2.4mg: 14.9% mean weight loss vs 2.4% placebo. The landmark trial.

STEP 2 (Lancet, 2021): Participants with both Type 2 diabetes and obesity. Demonstrated both glycemic improvement and weight reduction.

STEP 3 (JAMA, 2021): Combined with intensive behavioral therapy. Showed semaglutide adds benefits even on top of structured intervention.

STEP 4 (JAMA, 2021): The withdrawal study. 803 participants lost 10.6% over 20 weeks. Those who stopped regained; those who continued maintained loss. Proved the mechanism is ongoing.

STEP 5 (Nature Medicine, 2022): 2-year extension. Weight reduction sustained over 104 weeks.

STEP UP (Lancet, 2025): Higher dose (7.2mg). Even greater weight reduction. 95 sites, 11 countries.

What the Combined Data Shows

• ~15% weight loss with 2.4mg over 68 weeks (STEP 1)
• Stopping = regain — ongoing mechanism, not a reset (STEP 4)
• Higher dose = greater effect — 7.2mg showed more reduction (STEP UP)
• Glycemic improvements — 3,375 adults showed significant metabolic benefits (cross-trial analysis)
• 2-year durability — effects sustained (STEP 5)

Source: Wilding, J.P.H., et al. NEJM, 384, 989–1002. NEJM

Source: JAMA, 325(14), 1414–1425. JAMA

Source: STEP UP, Lancet, 2025. Lancet

The GLP-1 Mechanism

GLP-1 is a natural incretin hormone released from L-cells after eating:

• Insulin secretion — glucose-dependent, reducing hypoglycemia risk
• Glucagon suppression — prevents excess liver glucose release
• Gastric emptying — slows food transit, extending fullness
• Brain appetite regulation — hypothalamus and brainstem GLP-1 receptors control hunger and food reward

Native GLP-1 degrades within minutes. Semaglutide’s half-life is ~1 week, enabling once-weekly dosing.

The Brain Connection

• Reduces hunger signaling
• Decreases food reward (hedonic eating)
• Increases satiety after smaller meals

Semaglutide in Context

• Before: Few pharmacological options for weight management. Lifestyle alone: ~3-5% loss.
• After: ~15% weight loss — magnitude previously only with bariatric surgery.
• Downstream: Semaglutide’s success triggered tirzepatide and retatrutide development.

What Makes Semaglutide Different from Other GLP-1s

• Once-weekly dosing — vs daily (liraglutide) or twice-daily (exenatide)
• Greater weight reduction — ~15% vs ~5-10% for earlier GLP-1 agonists
• Structural modifications — amino acid substitutions + C-18 fatty diacid chain for extended circulation
• CNS penetration — potentially greater brain access than earlier compounds

Frequently Asked Questions

How does semaglutide work?
GLP-1 receptor agonist. Mimics natural GLP-1: stimulates insulin, suppresses glucagon, slows gastric emptying, regulates brain appetite centers.

What were STEP 1 results?
1,961 adults, 68 weeks. 14.9% mean weight loss vs 2.4% placebo. NEJM, 2021.

What did STEP 4 prove?
Stopping treatment leads to weight regain. The mechanism is ongoing, not a one-time reset.

What is STEP UP?
2025 Phase 3b trial. Higher dose (7.2mg). Greater weight reduction. Lancet publication.

How does it compare to tirzepatide?
Semaglutide: single GLP-1 (~15%). Tirzepatide: dual GIP/GLP-1 (~22.5%). Tirzepatide adds a second receptor.

Is semaglutide FDA-approved?
Yes. Type 2 diabetes (2017, Ozempic). Chronic weight management (2021, Wegovy).

Explore Semaglutide from Choice Peptide Labs

10mg vial · Published COA · USA-stocked · Cold-chain shipped

Disclaimer: For educational purposes only. Semaglutide is an FDA-approved medication. Research-grade compounds from Choice Peptide Labs are for laboratory research use only.